U.S., Sept. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07830342) titled 'A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer' on Sept. 15.
Brief Summary: A Single-Arm, Open-Label, Interventional Study to Evaluate the Efficacy of HS-IT101 Autologous Tumor-Infiltrating Lymphocyte (TIL) Cell Therapy After Lymphodepleting Preconditioning with Fludarabine and Cyclophosphamide and Subsequent Interleukin-2 Therapy in Patients with Advanced Non-Small Cell Lung Cancer.
Study Start Date: Oct., 2026
Study Type: INTERVENTIONAL
Condition:
Advanced NSCLC
Intervention:
DRUG: Cyclophosphamid
Cyclophosphamide administered via intravenous infusion once daily for 3 consecutiv...